Ascendis Pharma (ASND) officer exits 19,460 shares in open-market sale

Rhea-AI Filing Summary

Ascendis Pharma A/S officer Flemming Steen Jensen sold all his reported holdings in a single transaction. On May 11, 2026, he executed an open-market sale of 19,460 Ordinary Shares at an average price of $238.4903 per share, leaving 0 shares directly owned after the trade.

Insider Trade Summary

Net Seller: 19,460 shares ($4,641,021)

Net Sell 1 txn

Insider JENSEN FLEMMING STEEN

Role See Remarks

Sold 19,460 shs ($4.64M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	19,460	$238.4903	$4.64M

Holdings After Transaction: Ordinary Shares — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 19,460 shares Average sale price: $238.4903 per share Proceeds from sale (implied): Approximately $4.64 million +2 more

5 metrics

Shares sold 19,460 shares Open-market sale on May 11, 2026

Average sale price $238.4903 per share Open-market sale of Ordinary Shares

Proceeds from sale (implied) Approximately $4.64 million 19,460 shares at $238.4903 per share

Shares owned after transaction 0 shares Total_shares_following_transaction field

Net share change -19,460 shares transactionSummary netBuySellShares

Key Terms

Ordinary Shares, open-market sale, Form 4

3 terms

Ordinary Shares financial

"The insider sold 19,460 Ordinary Shares of Ascendis Pharma"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"he executed an open-market sale of 19,460 Ordinary Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"Ascendis Pharma reported this insider transaction in a Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JENSEN FLEMMING STEEN

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/11/2026		S		19,460	D	$238.4903	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

EVP & Product Supply and Quality

	/s/ Michael Wolff Jensen as attorney-in-fact for Flemming Jensen	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ascendis Pharma (ASND) report in this Form 4?

Ascendis Pharma reported that officer Flemming Steen Jensen completed an open-market sale of 19,460 Ordinary Shares. The shares were sold at an average price of $238.4903 per share, and this transaction eliminated his reported direct ownership position.

How many Ascendis Pharma (ASND) shares did the insider sell and at what price?

The insider sold 19,460 Ordinary Shares of Ascendis Pharma at an average price of $238.4903 per share. This single transaction represents the entire quantity disclosed in the filing and was classified as an open-market or private sale.

Does the Ascendis Pharma (ASND) insider still hold shares after this transaction?

According to the Form 4, the insider’s direct holdings fell to 0 Ordinary Shares after the transaction. The total_shares_following_transaction field shows 0.0000 shares, indicating no remaining directly owned shares reported in this filing.

What transaction code was used in the Ascendis Pharma (ASND) Form 4 filing?

The transaction used code “S,” indicating a sale in an open market or private transaction. The filing further labels it as an open-market sale of Ordinary Shares, aligning with SEC coding for a straightforward disposition of equity.

Was this Ascendis Pharma (ASND) insider transaction a buy or a sell?

The Form 4 classifies the transaction as a sell. The transaction_direction field shows “sell,” and the transaction_action is “open-market sale,” confirming it as a disposition rather than an acquisition of Ascendis Pharma shares.